GPT and metabolic dysfunction-associated steatotic liver disease: Another study on Ipragliflozin in patients with diabetes and NAFLD also reported a significant decrease in the ALT and γ-GTP levels, along with the pathological improvement of NAFLD [42]; thus, luseogliflozin might reduce the risk of and improve NAFLD.